A woman sitting down in a test lab looking at some test tubes

Therapeutic focus » Projects

A compound of competence

OUR FOCUS is on PN6047, a novel potent and selective, biased delta-opioid receptor agonist, which is predicted to reduce common symptoms of chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.

In various pre-clinical studies, PN6047 has shown high selectivity and potency, and very convincing efficacy in reducing neuropathic pain without any indications of the unwanted side effects of traditional opioids such as respiratory depression and abuse potential.

PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans. Its metabolic profile also indicates possibilities for developing combination therapies.

PN6047 has fully drug-able properties and characteristics supporting asolid dosage form.

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌